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The contracting muscle has been shown to act as an endocrine organ, secreting ‘‘myokines’’ that participate
in tissue crosstalk. In this issue of Cell Metabolism, Roberts et al. (2014) identify BAIBA as a contraction-
induced myokine that results in browning of white adipose tissue and increases fat oxidation in the liver.Over the last decade, it has become clear
that skeletal muscle can act as an endo-
crine organ that secretes several cyto-
kines and peptides termed ‘‘myokines’’
(Pedersen and Febbraio, 2012). Physical
activity protects against all causes of
mortality (Blair et al., 1995), and the iden-
tification of skeletal muscle as an endo-
crine organ (Febbraio et al., 2004)
provided mechanistic insight into the
disease-preventative effects of regular
physical activity, which include weight
loss in obese or overweight people. In
this issue of Cell Metabolism, Roberts
et al. (2014) demonstrate that the con-
tracting muscle cells secrete the metabo-
lite b-aminoisobutyric acid (BAIBA), which
mediates signaling processes in white
adipose tissue (WAT) and liver, leading
to weight loss and enhanced glucose
tolerance in mice (Roberts et al., 2014).
Peroxisome proliferator-activated re-
ceptor g coactivator-1a (PGC1a) is a
master transcriptional coactivator that
appears to be obligatory in the control of
energy metabolism (Handschin and Spie-
gelman, 2008). Initially discovered for its
role in promoting the thermogenic pro-
graming of brown adipose tissue (BAT),
PGC1a was subsequently identified as a
major regulator of skeletal muscle fiber
type, crucial in the adaptation of this
organ to exercise (Handschin and Spie-
gelman, 2008). However, the observation
that muscle-specific PGC1a-deficient
mice displayed a b cell phenotype (Hand-
schin et al., 2007) prompted the Spiegel-
man laboratory to investigate whether
this effect was due to the secretion of
one or more myokines. Indeed, Bostro¨m
et al. (2012) demonstrated that the con-
tracting skeletal muscle secreted Irisin,
a cleaved product of the protein fibro-
nectin type 3 domain-containing protein
5 (FNDC5), into the blood in a PGC1a-
dependent manner (Bostro¨m et al.,2012). This work from the Spiegelman
group demonstrated that Irisin could act
as a fat ‘‘browning’’ agent by promoting
the development of brown-like adipo-
cytes within subcutaneousWAT (Bostro¨m
et al., 2012). Given that BAT can oxidize
high levels of glucose and lipids to
generate heat, the activation or the devel-
opment of BAT in humans holds high
potential as a therapy for metabolic dis-
eases (Cannon and Nedergaard, 2004).
In light of these previous observations,
Roberts et al. (2014) sought to determine
if any additional mechanisms were in-
volved in mediating tissue crosstalk from
skeletal muscle to other organs during
muscle contraction. Using the same initial
model of exercise-mimicking myocytes
overexpressing PGC1a, the authors an-
alyzed the myocyte secretome through a
liquid chromatography-mass spectrom-
etry metabolic profiling technique. This
approach identified four metabolites that
were significantly increased in the high-
PGC1a conditions (Roberts et al., 2014).
These metabolites were then added to
primary adipocytes derived from subcu-
taneous inguinal fat pads to test their
ability to act on fat tissue. One such
secretory factor, a metabolite derived
from valine and thymine catabolism,
BAIBA, potentiated the expression of
brown adipocyte-specific genes such as
Uncoupled Protein-1 (UCP1) and Cell
Death-Inducing DFFA-like effector a
(CIDEA).
The authors then confirmed that the
addition of BAIBA to human induced
pluripotent stem cells, under conditions
that would normally result in white adipo-
cyte differentiation, instead led to a brown
adipocyte-like gene expression signature.
Moreover, functional in vitro measures,
such as cellular glucose uptake and
respiratory capacity, were also affected.
Importantly, the authors recapitulatedCell Metabolismthese findings in vivo by demonstrating
that muscle-specific PGC1a overexpres-
sion or, indeed, exercise increases the
circulating BAIBA concentration in mice.
In addition, BAIBA treatment in vivo led
to increased BAT-specific gene expres-
sion in the inguinal WAT, and this was
associated with decreased weight gain
and improved glucose tolerance in diet-
induced obese mice. The authors also
described enhanced b-oxidation in the
liver of BAIBA-treated animals but did
not report whether there was a subse-
quent improvement in hepatic steatosis
in the long-term-treated animals on a
high-fat diet, something that would be
of great interest. Interestingly, Roberts
et al. (2014) demonstrated that the effects
of BAIBA in both liver and adipose tissue
were dependent upon peroxisome pro-
liferator-activated receptor a (PPARa)
expression, a transcription factor not
only known as a master regulator of
b-oxidation but also reported to stimulate
the expression of UCP1 (Lee et al., 1995).
Accordingly, the effects of BAIBA on
peripheral tissues were abolished in
PPARa null mice or adipocytes and hepa-
tocytes pretreated with the selective
PPARa antagonist GW6471. Finally,
circulating BAIBA levels inversely corre-
lated with cardiometabolic risk factors in
humans. Thus this study elucidates an
additional mechanism that contributes to
the positive effects of exercise and shows
that BAIBA participates in tissue cross-
talk, being secreted by the contraction-
stimulated muscle and acting on liver
and fat tissues.
These findings raise several questions.
First, it would be interesting to measure
glucose uptake during a glucose chal-
lenge to quantify to what extent the
‘‘browning’’ of the subcutaneous adipose
tissue increases its glucose clearance
capacity, and whether this mechanism is19, January 7, 2014 ª2014 Elsevier Inc. 1
Figure 1. BAIBA Mediates the Positive Effects of Exercise
BAIBA is released from the muscle after an exercise bout, promoting differentiation of brown adipocyte-
like cells within subcutaneous fat depots and fat oxidation in the liver.
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tolerance profile. Second, the study did
not fully elucidate the mechanism by
which BAIBA acts on WAT and liver
(Figure 1). Consistent with the findings
described by Roberts et al. (2014), previ-
ous research has demonstrated that
BAIBA treatment prevents fat mass gain,
glucose intolerance, and hepatic steato-
sis in ob/+ mice fed a high-fat diet (Be-
griche et al., 2008). Intriguingly, the
same treatment in ob/ob mice fed a
normal chow diet did not lead to any of
these metabolic improvements, suggest-2 Cell Metabolism 19, January 7, 2014 ª2014ing that the effects of BAIBA are leptin
dependent. Indeed, ob/+ animals treated
with BAIBA had enhanced plasma leptin
levels (Begriche et al., 2008). It would be
interesting, therefore, to measure leptin
secretion in adipocytes treated with
BAIBA to understand if this effect is direct.
In conclusion, the current work under-
lines the importance of skeletal muscle
as an endocrine organ and provides
mechanistic insight into the positive
effects of exercise in disease prevention.
Furthermore, the current study confirms
that the adrenergic system does notElsevier Inc.have a monopoly on BAT activation,
opening up new therapeutic possibilities
for treating metabolic diseases.REFERENCES
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